LogoBiotechNW
The life science and biotech PR distribution service

New ambr® 15 fermentation Micro Scale Bioreactor System Provides Enhanced Microbial Strain Screening with Fed-Batch Capability

sarto-stedim-bio logo

Goettingen, Germany and Cambridge, UK, November 3, 2015 / B3C newswire / -- Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, today introduced the new ambr® 15 fermentation system, an automated micro bioreactor system designed to enhance microbial strain screening with advanced capabilities supporting fed-batch microbial cultures.

The new system, based on the gold-standard ambr 15 micro bioreactor technology, has been designed to meet the requirements of microbial fermentation.  It comprises 24 single-use stirred micro bioreactors (each with an 8-12mL working volume) integrated to a user-friendly, automated workstation. The system offers parallel processing and walk-away control of 24 micro bioreactors, providing fermentation scientists with efficient, consistent results from an enhanced early stage screening platform.

ambr 15 fermentation has been designed to deliver high oxygen transfer rates, rapid pH and feed additions and is ideally suited for assessing the effects of different strains with microbial cultures. The ambr 15 fermentation measures pH and DO every 12 seconds and there are pumped liquid lines for base and feed addition in each micro bioreactor, enabling tight pH control and a semi-continuous feed supply. Additionally, the 10mL working volume allows multiple samplings throughout the fermentation run to assess culture growth and protein production, thus providing more detailed process understanding.

The single-use micro bioreactor vessel contains an impeller suitable for fermentation and provides enhanced capability compared to shaking culture systems. The pH range of 6-8 is ideal for biopharm E. coli applications and cultures with similar requirements. As the ambr 15 vessels are single use and supplied sterile this eliminates cleaning and sterilization time, thus decreasing turnaround times between runs by many hours.

Dr Barney Zoro, ambr Product Manager at SSB explained: “Scientists have been trying to model microbial fermentation and screen microbial strains using shake plates and flasks but these devices are poor early stage models as they are not able to achieve representative cell densities, and do not allow monitoring and control of pH or DO. With these issues in mind, we developed ambr 15 fermentation and have data showing system consistency, repeatability and predictive selection of strains. This demonstrates that the system is an excellent tool for enhanced screening applications and we are confident that fermentation scientists will significantly reduce their time and resource demands when performing enhanced microbial strain selection studies using an ambr 15 fermentation system.”

ambr 15 fermentation is the latest addition to the ambr portfolio which also includes ambr 15 cell culture and ambr 250 systems.  ambr systems are widely used for cell line development and process optimisation at pharmaceutical, biotechnology and academic laboratories and are proven to provide a reliable model and consistent scalability to a range of upstream processes.

Image File

 ambr 15

Caption: New ambr® 15 fermentation micro bioreactor system designed to enhance microbial strain screening applications
For high resolution please click the image.


A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.


Contacts

Dominic Grone
Senior Manager Group Corporate Communications
Sartorius Stedim Biotech
+49 (0)551.3083324
This email address is being protected from spambots. You need JavaScript enabled to view it.

Michaela McAdam
Marketing Communications Manager
Sartorius Stedim Biotech
+44 (0) 1763 227200
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok